Dr. Takeshi Yoshimoto – Cancer – Best Researcher Award

Dr. Takeshi Yoshimoto - Cancer - Best Researcher Award

University of Tsukuba Hospital - Japan

Author Profile

SCOPUS

🎓 Early academic pursuits

 Dr. Takeshi Yoshimoto began his academic journey in the medical sciences with a strong foundation in clinical education. he earned his m.d. from hiroshima university faculty of medicine in march 2008, followed by a ph.d. from the graduate school of biomedical and health sciences, hiroshima university in august 2022. during his formative years, his curiosity about cerebrovascular diseases led him to explore genetics, biomarkers, and translational medicine, laying the groundwork for his future research focus, which indirectly intersects with diagnostic technologies resembling the precision systems used in power electronics.

🧠 Professional endeavors

Dr. Yoshimoto's career showcases a rich progression through esteemed institutions. from his early role as an intern at fukushima coop hospital, he gradually ascended through ranks at national cerebral and cardiovascular center, serving as resident, senior resident, Cancer and later as a medical doctor under  distinguished mentors like dr. ihara and dr. toyoda. he also contributed to academia at hiroshima university and currently serves as a lecturer in the department of stroke and cerebrovascular diseases at university of tsukuba hospital. his consistent clinical involvement paired with academic appointments underlines his dual commitment to patient care and neurological research.

🧬 Contributions and research focus

A pioneer in translational stroke research, dr. yoshimoto focuses on integrating genetics with acute stroke management. his primary research involves developing algorithms for selecting clot removal devices by identifying genetic variations, particularly the moyamoya-related rnf213 p.r4810k polymorphism. he explores the association between juvenile strokes and serum biomarkers. his projects are comparable in Cancer precision and application-oriented design to power electronics, highlighting his innovative integration of medical diagnostics and genetic profiling to improve acute care strategies.

🌍 Impact and influence

Dr. Yoshimoto’s work has had significant impact on cerebrovascular research, especially in japan. his dedication to exploring the genetic underpinnings of stroke has advanced understanding of moyamoya disease and enhanced patient stratification for endovascular therapy. his influence is also evident in the repeated recognition he received at prestigious national and international conferences, positioning him as a leading voice Cancer in neurovascular translational research. the framework he established for genetic-based intervention selection has potential parallels with feedback and adaptive systems in power electronics, reflecting the precision and personalization he brings to neurology.

🏆 Academic cites and recognition

Dr. Yoshimoto’s excellence has been widely acknowledged. he received the paul dudley white international scholar award from the american heart association in 2021 and multiple presentation awards at the japan stroke society and japanese society of neuroendovascular therapy (jsnet). notably, he received teaching awards and outstanding paper honors, reinforcing his role Cancer as both a scholar and mentor. these accolades validate the academic rigor and practical relevance of his work, particularly his contributions to stroke genetics and device selection.

🔬 Legacy and future contributions

Dr. Yoshimoto is poised to continue shaping the future of stroke research with a strong emphasis on personalized medicine. he aims to refine and implement his clot removal device selection algorithm into broader clinical practice. further integration of genetic biomarkers into real-time therapeutic decision-making is expected. his work not only improves outcomes for stroke patients but also sets a model for interdisciplinary research convergence, similar to how power electronics evolved by merging physics, control theory, and electrical engineering.

Notable Publication

  • Title: Relationship Between RNF213 p.R4810K and Echocardiographic Findings in Patients with Cerebrovascular Diseases: A Multicenter Prospective Cohort Study
    Author(s): Kotaro Noda, Yorito Hattori, Tatsuya Nishii, Yoshikazu Nakaoka, Masafumi Ihara
    Journal: Journal of the American Heart Association, 2025

  • Title: Deep learning-based post hoc denoising for 3D volume-rendered cardiac CT in mitral valve prolapse
    Author(s): Tatsuya Nishii, Tomoro Morikawa, Hiroki Nakajima, Satsuki M. Fukushima, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2025

  • Title: Evaluation of the Efficacy and Accuracy of Super-Flexible Three-Dimensional Heart Models of Congenital Heart Disease Made via Stereolithography Printing and Vacuum Casting: A Multicenter Clinical Trial
    Author(s): Isao Shiraishi, Masaaki Yamagishi, Takaya Hoashi, Toshiaki Hisada, Kenichi Kurosaki
    Journal: Journal of Cardiovascular Development and Disease, 2024

  • Title: Pericardial adhesion and performance of hemodynamically significant constrictive pericarditis using cine magnetic resonance feature tracking
    Author(s): Yasutoshi Ohta, Midori Fukuyama, Yoshiaki Morita, Hiroki Horinouchi, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Laterality of CT-measured hepatic extracellular volume fraction in patients with chronic thromboembolic pulmonary hypertension
    Author(s): Tatsuya Nishii, Hiroki Horinouchi, Takara Namboku, Takeshi Ogo, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Covering the intercostal artery branching of the Adamkiewicz artery during endovascular aortic repair increases the risk of spinal cord ischemia
    Author(s): Yoshimasa Seike, Tatsuya Nishii, Kazufumi Yoshida, Tetsuya Fukuda, Hitoshi Matsuda
    Journal: JTCVS Open, 2024

Dr. Hui Jia – Tumor chemotherapy resistance – Best Researcher Award

Dr. Hui Jia - Tumor chemotherapy resistance - Best Researcher Award

Shenyang Medical College - China 

Author Profile 

SCOPUS 

Early academic pursuits 📚

Dr. Hui Jia's journey in traditional chinese medicine began with a solid academic foundation. she earned her bachelor of pharmacy from shenyang pharmaceutical university, which sparked her interest in natural medicine and pharmacology. pursuing further studies, she obtained a master’s degree in traditional chinese medicine from shaanxi university of traditional chinese medicine. in 2021, she completed her ph.d. in traditional chinese medicine from shenyang pharmaceutical university, where her research honed in on the bioactive compounds of medicinal herbs and their therapeutic potential.

Professional endeavors 🏛️

Dr. Jia is currently an associate professor at the school of traditional chinese medicine, shenyang medical college. she has played a key role in shaping the institution’s research focus on herbal medicines and natural products. her dedication to teaching and mentorship is evident, as she actively guides students in exploring the intricate mechanisms of traditional remedies, while leading significant research projects that address major health challenges like drug-resistant cancers.

Contributions and research focus 🔬

Dr. Hui jia’s primary research revolves around understanding the active ingredients of herbs and their molecular mechanisms, particularly in reversing drug Tumor chemotherapy resistance resistance. her work is centered on investigating the key protein targets of natural products. one of her significant contributions is her research on cimigenoside, a bioactive compound from cohosh, and its role in combating drug resistance in triple-negative breast cancer through the γ-secretase/nicd/notch-pxr axis. her innovative approach offers new insights into cancer treatment.

Accolades and recognition 🏅

Through her groundbreaking research, dr. jia has gained recognition in the scientific community. she has secured prestigious grants from both the national natural science foundation of china and liaoning province for her work on cancer drug resistance. her research projects reflect her excellence and leadership in the field of Tumor chemotherapy resistance traditional chinese medicine, addressing complex challenges in cancer treatment and advancing the potential of natural products as therapeutic agents.

Impact and influence 🌍

Dr. jia's research has far-reaching implications, particularly in the realm of cancer therapeutics. her work on γ-secretase inhibitors and their role in reversing drug resistance in triple-negative breast cancer highlights the importance of integrating traditional medicine with modern science. her studies provide new avenues for Tumor chemotherapy resistance treating difficult cancers, potentially transforming how drug resistance is managed in clinical settings.

Legacy and future contributions 🔮

with her deep-rooted passion for traditional chinese medicine, dr. hui jia is set to leave a lasting legacy in the field. her future contributions are expected to further bridge the gap between traditional herbal medicine and contemporary drug discovery. as she continues to explore the bioactive compounds of natural products and their mechanisms of action, her work will undoubtedly influence future generations of researchers and contribute to innovative cancer therapies.

Notable Publications 

  1. Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling
    Authors: Zhang, Y., Qu, Y., Cai, R., Ren, F., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 976, 176699
  2. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance
    Authors: Feng, M., Santhanam, R.K., Xing, H., Zhou, M., Jia, H.
    Journal: Biochemical Pharmacology, 2024, 220, 115991
  3. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling
    Authors: Xu, Q., Zhuo, K., Zhang, X., Dong, J., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 962, 176252
  4. Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases
    Authors: Kang, M., Jia, H., Feng, M., Zhang, L., Zhou, M.-S.
    Journal: Frontiers in Immunology, 2024, 15, 1467089
  5. Cigarette smoke-induced exosomal miR-221-3p facilitates M1 macrophage polarization via the STAT3 pathway in chronic obstructive pulmonary disease
    Authors: Jia, H., He, W., Wu, B., Wang, M., Xia, S.
    Journal: Aging, 2024, 16(17), pp. 12379–12391